AstraZeneca (AZ, NASDAQ: AZN)’s China unit is set to undergo significant organizational changes, including the establishment of a new business department and three C-suite appointments, as reported by local media.
Chen Kangwei, currently the General Manager of AstraZeneca’s China oncology division, will relocate to Singapore for family reasons, taking on the role of Business Manager for AstraZeneca’s Asia (AA) business unit. He will join the AA management team and report to Sylvia Varela, Vice President of AstraZeneca Asia. In his absence, Lai Minglong, the General Manager of AstraZeneca China, will also assume leadership of the oncology division, continuing to report to Wang Lei, President of AstraZeneca International Business and China.
The company will officially establish the China Biopharmaceutical Business Unit (BBU), to be led by Lin Xiao, who heads the Respiratory Inhalation and Biological Products Division and oversees operations in Hong Kong and Macau. Following these adjustments, Chen Kangwei will exit the leadership team in China, while Lai Minglong will take full responsibility for AstraZeneca’s largest business unit in the region—the oncology division. Lin Xiao will manage the newly formed BBU, focusing on chronic disease business development and specific operations in Hong Kong and Macau.- Flcube.com
